SRT Stock Chart & Stats
CHF163.18
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF163.18
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF158.56 - CHF187.73
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
CHF14.16B
Enterprise ValueCHF17.90K
Total Cash (Recent Filing)CHF306.90M
Total Debt (Recent Filing)CHF4.05B
Price to Earnings (P/E)88.5
Beta0.75
Next Earnings
Oct 22, 2026EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.83
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.95
Revenue Forecast (FY)CHF3.47B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthConsumables create repeat demand because customers require them for ongoing biopharmaceutical production. Their double-digit growth since 2019 and strong H1 performance support revenue visibility and reinforce Sartorius’s embedded customer relationships.
Growth And Margin RecoveryConfirmed growth and profitability targets indicate that the recovery is broad enough to support sustained improvement rather than relying only on temporary demand. Bioprocess Solutions is expected to combine 6–10% growth with an approximately 32% margin.
Improving Cash GenerationStronger operating and free cash flow improves the company’s ability to fund capital investment, support innovation and reduce leverage internally. The reported deleveraging progress provides additional financial resilience if biopharma spending becomes uneven.
Bears Say
Elevated LeverageMeaningful debt remains a constraint for a medical-instruments supplier, particularly while returns are moderate. Leverage can limit flexibility for acquisitions, capacity expansion and research investment if operating conditions weaken or interest costs remain high.
Weak Bottom-line ConversionAlthough EBIT margins have recovered, low net profitability shows that financing, tax or other below-operating costs still absorb a substantial share of earnings. Uneven cash conversion makes the recovery less dependable and limits internally generated financial capacity.
Customer Timing And Equipment WeaknessDelayed cell- and gene-therapy orders can shift revenue into late 2026 or 2027, creating execution risk around the growth outlook. At the same time, slower equipment recovery may restrain cross-selling and leave performance more dependent on consumables.
Sartorius News
SRT FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was CHF158.56 and its highest was CHF187.73 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is CHF14.16B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Oct 22, 2026 which is in 55 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Jul 23, 2026. The company reported CHF1.208 earnings per share for the quarter, missing the consensus estimate of CHF1.233 by -CHF0.025.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Overvalued.
Does Sartorius AG pay dividends?
Sartorius AG does not currently pay dividends.
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.17.
How many shares outstanding does Sartorius AG have?
Currently, no data Available
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of CHF1.208 in its last earnings report, missing expectations of CHF1.233. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in CH:SRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―